Covista (CVSA) Aktievy
Covista Inc. tillsammans med sina dotterbolag tillhandahåller vårdutbildning i USA, Barbados, St. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
CVSA Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Covista Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$131.46 |
| 52 veckors högsta | US$156.26 |
| 52 veckors lägsta | US$86.97 |
| Beta | 0.62 |
| 1 månads förändring | 11.41% |
| 3 månaders förändring | 4.33% |
| 1 års förändring | 1.72% |
| 3 års förändring | 208.23% |
| 5 års förändring | 269.48% |
| Förändring sedan börsintroduktionen | 10,686.46% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • Aug 11
CVSA: Leadership Expansion And Healthcare Education Demand Will Drive Future Upside
Covista's analyst price target has shifted from $153.25 to $159.50, with analysts pointing to the recent fiscal Q4 results and their view that demand for healthcare professionals will continue to outpace supply as key supports for the updated valuation inputs. What’s in the News for Covista Covista expanded its leadership structure with an enlarged role for Scott Liles, who now leads corporate strategy and a new Performance Acceleration Office while continuing as President of the Medical and Veterinary segment.
Uppdatering av berättelse • Jun 26
CVSA: Student Enrollment Momentum And Campus Expansion Will Support Future Upside
The analyst price target for Covista has increased from $130 to $140, with analysts citing updated assumptions on revenue growth, profit margins, and future P/E as the key reasons for the change. What’s in the News for Covista Covista raised its fiscal 2026 revenue guidance to a range of approximately US$1.93b to US$1.945b, compared with the prior range of US$1.9b to US$1.94b, with guidance implying about 8% to 9% year-over-year growth.Seeking Alpha • Jun 03
Covista: Healthcare Education Growth At A Fair Price
Summary Covista (CVSA) is rated Hold, reflecting strong healthcare education positioning but a valuation that prices in much of its growth story. CVSA's enrollment growth, AI-enabled offerings, and robust cash flow support its strategic pivot, yet it trades near peer medians on key valuation multiples. Regulatory risks tied to Title IV funding and ongoing lawsuits warrant a risk premium, tempering the case for aggressive buying at current levels. Peers like PRDO offer lower multiples and stronger cash conversion, while LOPE commands a premium for a cleaner balance sheet and superior cash generation. Read the full article on Seeking AlphaNy berättelse • Apr 22
Health Care Workforce Shortages Will Pressure Capacity Expansion Yet Support Long Term Potential
Catalysts About Covista Covista is a health care education provider focused on training nurses, physicians, veterinarians and behavioral health professionals at scale. What are the underlying business or industry changes driving this perspective?Ny berättelse • Apr 08
Health Care Workforce Shortages And Digital Learning Will Support This Bullish Long Term Thesis
Catalysts About Covista Covista provides higher education programs focused on health care and related professional fields. What are the underlying business or industry changes driving this perspective?
Ny berättelse • Mar 24
Health Care Workforce Shortages And Flexible Learning Will Support Stronger Long Term Outcomes
Catalysts About Covista Covista focuses on large scale health care education programs serving nursing, medical, veterinary and allied health students across the United States. What are the underlying business or industry changes driving this perspective?Analysartikel • Sep 27
With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysartikel • Aug 07
Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet
NYSE:ATGE 1 Year Share Price vs Fair Value Explore Adtalem Global Education's Fair Values from the Community and select...Analysartikel • Jul 07
An Intrinsic Calculation For Adtalem Global Education Inc. (NYSE:ATGE) Suggests It's 44% Undervalued
Key Insights Adtalem Global Education's estimated fair value is US$221 based on 2 Stage Free Cash Flow to Equity...Analysartikel • May 13
There's Reason For Concern Over Adtalem Global Education Inc.'s (NYSE:ATGE) Massive 27% Price Jump
Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders have had their patience rewarded with a 27% share price jump...Analysartikel • May 07
If EPS Growth Is Important To You, Adtalem Global Education (NYSE:ATGE) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysartikel • Apr 24
Is Adtalem Global Education (NYSE:ATGE) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Mar 25
Adtalem Global Education Inc. (NYSE:ATGE) Shares Could Be 48% Below Their Intrinsic Value Estimate
Key Insights Adtalem Global Education's estimated fair value is US$198 based on 2 Stage Free Cash Flow to Equity...Analysartikel • Mar 11
Subdued Growth No Barrier To Adtalem Global Education Inc.'s (NYSE:ATGE) Price
With a median price-to-earnings (or "P/E") ratio of close to 17x in the United States, you could be forgiven for...Analysartikel • Feb 24
Is There Now An Opportunity In Adtalem Global Education Inc. (NYSE:ATGE)?
Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it saw a decent share price...Seeking Alpha • Feb 21
Adtalem Global Education: Surging On Registered Nurse Shortage
Summary Adtalem Global Education Inc.'s financial performance has surged with an underlying nationwide shortage of Registered Nurses and in mental health professionals. A shortage is expected to persist — Adtalem still looks to benefit from secular trends in an aging population, while the long-term performance depends on universities' ability to expand capacity. ATGE stock's surge already reflects a good mid-term earnings performance, making long-term growth required for significant returns. I estimate a fair value of $109.5. Read the full article on Seeking AlphaAnalysartikel • Jan 21
With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysartikel • Dec 19
These 4 Measures Indicate That Adtalem Global Education (NYSE:ATGE) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 17
Adtalem Global Education Still Offers Competitive PEG Ratio And Substantial Share Buybacks
Summary The company has shown significant financial progress with improving EBIT and profit margins, indicating efficient cost management. Current valuation metrics suggest the company is rather cheaply priced, despite the good run in 2024. The future outlook remains positive, but investors should be aware of potential risks, such as the debt or future competitive threats from robotics. Read the full article on Seeking AlphaAnalysartikel • Nov 26
Adtalem Global Education Inc.'s (NYSE:ATGE) Shares Climb 27% But Its Business Is Yet to Catch Up
Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders would be excited to see that the share price has had a great...Analysartikel • Oct 31
Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?
Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it led the NYSE gainers with a...Analysartikel • Oct 16
Should You Be Adding Adtalem Global Education (NYSE:ATGE) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Oct 04
Adtalem Global Education Faces Problems But Is Growing Steadily
Summary Adtalem Global Education focuses on medical and veterinary education, showing solid profitability and potential growth in a booming healthcare industry. Despite a current ratio below 1.0, ATGE maintains a reasonable price/book ratio and generates significant operating cash flow, indicating financial stability. Risks include reliance on government financial aid, maintaining accreditation, and ensuring student placements in healthcare jobs, which are crucial for sustaining reputation and revenue. With projected revenue growth and a forward P/E ratio of 13.12, Adtalem Global is a cautious buy, offering portfolio diversity in a growing sector. Read the full article on Seeking AlphaAnalysartikel • Sep 16
Adtalem Global Education (NYSE:ATGE) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Aug 29
Adtalem Global Education Inc.'s (NYSE:ATGE) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20.7x Adtalem Global Education Inc. ( NYSE:ATGE ) may be sending bearish...Analysartikel • Aug 14
We Think Adtalem Global Education's (NYSE:ATGE) Robust Earnings Are Conservative
Even though Adtalem Global Education Inc.'s ( NYSE:ATGE ) recent earnings release was robust, the market didn't seem to...Aktieägarnas avkastning
| CVSA | US Consumer Services | US Marknad | |
|---|---|---|---|
| 7D | 3.9% | -2.3% | 0.1% |
| 1Y | 1.7% | -18.2% | 18.9% |
Avkastning vs industri: CVSA översteg US Consumer Services branschen som gav -18.2 % under det senaste året.
Avkastning vs Marknaden: CVSA presterade sämre än US marknaden som gav 18.9 % under det senaste året.
Prisvolatilitet
| CVSA volatility | |
|---|---|
| CVSA Average Weekly Movement | 7.9% |
| Consumer Services Industry Average Movement | 8.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: CVSA har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: CVSA s veckovolatilitet ( 8% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1987 | 4,754 | Steve Beard | www.covista.com |
Covista Inc. bedriver tillsammans med sina dotterbolag utbildning inom hälso- och sjukvårdsområdet i USA, Barbados, Saint Kitts och Saint Maarten. Företaget är verksamt inom tre segment: Chamberlain, Walden samt medicin och veterinärmedicin. Företaget erbjuder utbildningsprogram som leder till akademiska examina, däribland kandidat-, magister- och doktorsexamina, samt onlinebaserade certifikatprogram inom omvårdnad, hälso- och sjukvårdsyrken, medicinsk och veterinärmedicinsk eftergymnasial utbildning, rådgivning, ekonomi, informationsteknik, psykologi, folkhälsa, socialt arbete och socialtjänst, offentlig förvaltning och offentlig politik samt straffrätt.
Covista Inc. Sammanfattning av grunderna
| CVSA grundläggande statistik | |
|---|---|
| Börsvärde | US$4.50b |
| Vinst(TTM) | US$267.38m |
| Intäkter(TTM) | US$1.95b |
16.7x
P/E-förhållande2.3x
P/S-förhållandeÄr CVSA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| CVSA resultaträkning (TTM) | |
|---|---|
| Intäkter | US$1.95b |
| Kostnad för intäkter | US$833.66m |
| Bruttovinst | US$1.12b |
| Övriga kostnader | US$853.05m |
| Intäkter | US$267.38m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 7.86 |
| Bruttomarginal | 57.34% |
| Nettovinstmarginal | 13.68% |
| Skuld/egenkapitalförhållande | 45.8% |
Hur har CVSA utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/18 01:48 |
| Aktiekurs vid dagens slut | 2026/08/18 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2026/06/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Covista Inc. bevakas av 24 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Gary Bisbee | Barclays |
| Gary Prestopino | Barrington Research Associates, Inc. |
| Alexander Paris | Barrington Research Associates, Inc. |